In a groundbreaking advancement in cancer research, a team from the Germans Trias i Pujol Research Institute (IGTP), in collaboration with the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan Institute of Oncology (ICO), has engineered a novel cellular model that intricately replicates the progression of neurofibromatosis type 1 (NF1)-associated tumors. This new model, derived from induced pluripotent stem cells (iPSCs), offers an unprecedented window into the molecular progression of these tumors, ranging from benign manifestations to aggressive malignant peripheral nerve sheath tumors (MPNST). Published in the prestigious journal Nature Communications, this study not only elucidates the complex biology underlying NF1 tumor evolution but also highlights promising therapeutic avenues, notably the drug combination of olaparib and selumetinib.
NF1 is a genetic disorder characterized by the development of tumors originating in the peripheral nervous system. While many of these tumors remain benign, their potential transformation into malignant peripheral nerve sheath tumors—a rare and aggressive sarcoma subtype—poses significant clinical challenges due to limited effective treatment options currently available. The malignant transformation process has been notably difficult to study, primarily because of the absence of reliable models that faithfully recapitulate tumor progression in a controlled laboratory environment. The ingenious application of iPSC technology by the IGTP-led team attempts to bridge this critical gap.
By genetically modifying iPSCs to harbor sequential molecular alterations typical of NF1 tumorigenesis, researchers created a dynamic system capable of mimicking the cellular and genetic events as neurofibromas transform into malignant MPNSTs. This model precisely mirrors the gradual phenotypic changes and genetic reprogramming that underlie tumor progression, providing a versatile and manipulable platform to dissect the complex pathways involved. The use of iPSCs, which maintain pluripotency yet can be directed along specific lineages, allowed for the observation of tumor evolution in a way that traditional models could not achieve, marking a significant leap forward in cancer modeling.
A pivotal insight from this investigation centers on the role of the Polycomb Repressive Complex 2 (PRC2), a key epigenetic regulator. The loss of PRC2 functionality emerged as a significant driver of malignant transformation, effectuating widespread reorganization of chromatin architecture and misregulation of gene expression. Such epigenetic alterations appear to catalyze the transition to more aggressive tumor phenotypes by endowing cells with enhanced proliferative and invasive capacities, hallmarks of malignant MPNSTs. The identification of PRC2 loss as a molecular switch highlights a potential biomarker and target for therapeutic intervention.
Harnessing this sophisticated model, the researchers embarked on an expansive drug screening campaign, evaluating hundreds of compounds for their efficacy against NF1 tumor progression. Intriguingly, tumors harboring PRC2 alterations demonstrated a pronounced sensitivity to inhibition of poly (ADP-ribose) polymerase (PARP), a class of enzymes integral to DNA repair mechanisms. PARP inhibitors, like olaparib, have previously gained traction for treating cancers with defective DNA repair pathways, including certain breast and ovarian cancers. The identification of this vulnerability in MPNST models unveils a promising therapeutic axis.
Furthermore, the combination of olaparib with selumetinib—a selective MEK inhibitor known to interfere with the MAPK signaling pathway often hyperactivated in NF1-associated tumors—resulted in significant tumor growth reduction in preclinical systems. This synergistic drug pairing capitalizes on exploiting both the defective epigenetic landscape and aberrant signaling circuits within malignant cells, providing a dual-pronged strategy for enhanced efficacy. These results lay the groundwork for future clinical investigations aiming to translate these findings into tangible treatment regimens for patients afflicted with NF1-related malignancies.
The study embodies a substantial multidisciplinary effort, integrating expertise in hereditary cancer genetics, translational cancer genomics, and bioinformatics. By leveraging genomic editing tools and high-throughput screening capabilities, the researchers not only charted the stepwise molecular events behind tumor progression but also innovatively identified novel therapeutic targets. Such integrative approaches underscore the paradigm shift in oncology research from descriptive studies to mechanism-based precision medicine.
This research holds broader implications beyond NF1, as it exemplifies how disease modeling using patient-derived pluripotent stem cells can unravel the intricacies of tumor biology and identify context-specific drug sensitivities. The ability to model glial to neuro-mesenchymal transition—an essential process characterized by shifts in cellular phenotype and gene expression—further enriches the understanding of tumor heterogeneity and plasticity. These insights are vital for overcoming therapeutic resistance and developing more effective, tailored interventions in oncology.
Eduard Serra and Meritxell Carrió, the co-senior authors from IGTP, emphasize that their model not only provides a powerful research platform to interrogate tumor progression mechanisms but also serves as a pragmatic tool for screening therapeutics in tumors characterized by limited treatment options. Their first author, Itziar Uriarte, highlights how this work integrates into her doctoral research, reflecting the capacity of stem cell technology to revolutionize cancer studies and therapeutic discovery.
The project received pivotal funding support from renowned institutions such as La Marató de TV3, the Children’s Tumor Foundation, and the Instituto de Salud Carlos III, underscoring the collaborative investment into rare disease research. This confluence of international expertise and resources attests to the high scientific and clinical significance attributed to tackling NF1-associated tumor malignancies.
Moving forward, the team aims to refine their model further to capture additional layers of tumor microenvironment interactions and unravel resistance mechanisms to combination therapy. By doing so, they aspire to accelerate the translation of laboratory discoveries into effective clinical applications, potentially improving prognosis and quality of life for patients struggling with neurofibromatosis-associated malignant tumors.
This study charts a transformative course in cancer research, merging innovative stem cell technology with targeted drug discovery to confront one of the most challenging neurocutaneous tumor syndromes. Its findings promise to inform future therapeutic paradigms and enhance the scientific understanding of malignant peripheral nerve sheath tumors at a molecular level, ultimately contributing to more hopeful clinical outcomes.
Subject of Research: Cells
Article Title: Induced pluripotent stem cell–derived models of malignant nerve sheath tumor progression mimic glial to neuro-mesenchymal transition and uncover therapeutic opportunities
News Publication Date: 17-Jun-2026
Web References: https://doi.org/10.1038/s41467-026-73119-8
References:
Uriarte-Arrazola, I., Magallón-Lorenz, M., Fernández-Rodríguez, J. et al. Induced pluripotent stem cell-derived models of malignant nerve sheath tumor progression mimic glial to neuro-mesenchymal transition and uncover therapeutic opportunities. Nat Commun 17, 5361 (2026). DOI: 10.1038/s41467-026-73119-8
Image Credits: Bellvitge Biomedical Research Institute (IDIBELL), Catalan Institute of Oncology, Germans Trias i Pujol Research Institute (IGTP)
Keywords: Neurofibromatosis, Induced pluripotent stem cells, Tumor progression, Malignant peripheral nerve sheath tumors, PRC2 complex, Epigenetic regulation, PARP inhibitors, Olaparib, Selumetinib, Cancer modeling, Drug discovery, Glial to neuro-mesenchymal transition
